SoftOx Solutions

SOFTX

NO0010811961

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2026-01-16 am EST			5-day change	1st Jan Change
0.0690 ^NOK	-3.63%		-5.48%	-21.41%

Dec. 29	Danish Medicines Agency Approves Phase 2A Trial for Softox Inhalation Solution	CI
Dec. 29	SoftOx Solutions Lands Approval for Inhalation Therapy's Mid-stage Study in Denmark	MT

SoftOx Solutions Issues 60 Million Shares to Long State Investments

Published on 11/28/2025 at 11:02 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about SoftOx Solutions

Dec. 29	Danish Medicines Agency Approves Phase 2A Trial for Softox Inhalation Solution	CI
Dec. 29	SoftOx Solutions Lands Approval for Inhalation Therapy's Mid-stage Study in Denmark	MT
Nov. 28	SoftOx Solutions Issues 60 Million Shares to Long State Investments	MT
Nov. 28	Softox Solutions resolved on private placement	RE
Nov. 26	SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 14	Softox Solutions as Announces Gmp Drug Substance Successfully Manufactured - Key Milestone for Cf and Edf Clinical Programs	CI
25-10-16	SoftOx Solutions Unit Submits Clinical Trial Application for Inhalation Therapy	MT
25-10-16	SoftOx Defense Solutions AS Submits Phase 1 Clinical Trial Application Under the European Defence Fund Program	CI
25-10-06	SoftOx Solutions AS announced that it expects to receive NOK 1.149 million in funding from Long State Investments Limited	CI
25-10-01	SoftOx Solutions AS Announces Clinical Trial Application for Dose Escalation / Cystic Fibrosis Phase 2a	CI
25-09-25	SoftOx Solutions AS announced that it has received NOK 6 million in funding from Long State Investments Limited	CI
25-09-23	SoftOx Solutions AS Announces Data on the Stability of Hypochlorous Acid, the Core Component of Its Inhaled Therapy	CI
25-09-17	SoftOx Solutions AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-09-17	SoftOx Solutions Q2 operating loss narrows to NOK 3.3 million	RE
25-09-11	SoftOx Solutions exercises on financing facility with Long Stateoec	RE
25-09-08	SoftOx Solutions AS - Special Call
25-09-02	SoftOx Solutions AS Refines Clinical Focus and Advances into Chronic Lung Disease Treatments	CI
25-08-14	Softox Solutions secures committed financing facility	RE
25-08-13	SoftOx Solutions AS announced a financing transaction	CI
25-06-27	SoftOx Solutions AS Appoints Tore Duvold as New Board Member	CI
25-06-27	SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-26	SoftOx Solutions AS Auditor Raises 'Going Concern' Doubt	CI
25-03-26	SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
25-03-26	Softox Solutions Q4 Loss Before Tax Narrows To NOK 3.6 Mln	RE
25-03-25	Norway's SoftOx Solutions to Raise NOK9 Million via Private Placement	MT

SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOxâs product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 25 - Q4 2025 Earnings Release

More about the company